T Cell Depleted Peripheral Blood Stem Cell Allotransplantation with T Cell Add Back for Patients with Hematological Malignancies: Effect of Chronic GVHD on Outcome

Biology of Blood and Marrow Transplantation

Volumn 12, Issue 12, 2006, Pages 1318-1325

  Montero, Aldemar ^a   Savani, Bipin N ^a   Shenoy, Aarthi ^a   Read, Elizabeth J ^b   Carter, Charles S ^b   Leitman, Susan F ^b   Mielke, Stephan ^a   Rezvani, Katayoun ^a   Childs, Richard ^a   Barrett, A John ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Myeloablative; Peripheral blood stem cell transplantation; T cell depleted

Indexed keywords

ACICLOVIR; CALCIUM CHLORIDE; CITRIC ACID; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYCLOSPORIN A; FLUCONAZOLE; FLUDARABINE; FOSCARNET; GANCICLOVIR; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; STEROID; VALGANCICLOVIR;

ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ADULT; ARTICLE; CANCER RELAPSE; CD34 SELECTION; CHILD; CHRONIC GRAFT VERSUS HOST DISEASE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DONOR; DRUG DOSE REDUCTION; DRUG MEGADOSE; FEMALE; FOLLOW UP; HEMATOLOGIC MALIGNANCY; HLA TYPING; HUMAN; INTOXICATION; LEUKAPHERESIS; LOW DRUG DOSE; LYMPHOCYTE COUNT; LYMPHOCYTE TRANSFUSION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORTALITY; MULTIVARIATE ANALYSIS; MYELOABLATIVE CONDITIONING; OVERALL SURVIVAL; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PNEUMOCYSTOSIS; PROBABILITY; PROGNOSIS; RISK FACTOR; SIBLING; T CELL DEPLETION;

ADOLESCENT; ADULT; CHILD; CHRONIC DISEASE; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; GRAFT VS HOST DISEASE; GRAFT VS LEUKEMIA EFFECT; HEMATOLOGIC NEOPLASMS; HUMANS; INCIDENCE; INFECTION; LEUKOCYTE REDUCTION PROCEDURES; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; PULMONARY EDEMA; RECURRENCE; RISK FACTORS; SURVIVAL ANALYSIS; T-LYMPHOCYTES; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 33845259299     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2006.08.034     Document Type: Article

References (25)

1. Schmitz N., Beksac M., Hasenclever D., et al. Transplantation of mobilized peripheral blood cells to HLA-identical siblings with standard-risk leukemia. Blood 100 (2002) 761-767
2. Bensinger W.I., Martin P.J., Storer B., et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med 344 (2001) 175-181
3. Couban S., Simpson D.R., Barnett M.J., et al. A randomized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies. Blood 100 (2002) 1525-1531
4. Kernan N.A., Collins N.H., Juliano L., et al. Clonable T lymphocytes in T cell-depleted bone marrow transplants correlate with development of graft-v-host disease. Blood 68 (1986) 770-773
5. Lowenberg B., Wagemaker G., van Bekkum D.W., et al. Graft-versus-host disease following transplantation of 'one log' versus 'two log' T-lymphocyte-depleted bone marrow from HLA-identical donors. Bone Marrow Transplant 1 (1986) 133-140
6. Marmont A.M., Horowitz M.M., Gale R.P., et al. T-cell depletion of HLA-identical transplants in leukemia. Blood 78 (1991) 2120-2130
7. Solomon S.R., Nakamura R., Read E.J., et al. Cyclosporine is required to prevent severe acute GVHD following T-cell-depleted peripheral blood stem cell transplantation. Bone Marrow Transplant 31 (2003) 783-788
8. Speck B., Bortin M.M., Champlin R., et al. Allogeneic bone-marrow transplantation for chronic myelogenous leukaemia. Lancet 1 (1984) 665-668
9. Montero A., Savani B.N., Kurlander R., et al. Lineage-specific engraftment and outcomes after T-cell-depleted peripheral blood stem cell transplant with Flu/Cy/TBI conditioning. Br J Haematol 130 (2005) 733-739
10. Thomas E., Storb R., Clift R.A., et al. Bone-marrow transplantation (first of two parts). N Engl J Med 292 (1975) 832-843
11. Mavroudis D., Read E., Cottler-Fox M., et al. CD34+ cell dose predicts survival, posttransplant morbidity, and rate of hematologic recovery after allogeneic marrow transplants for hematologic malignancies. Blood 88 (1996) 3223-3229
12. Bahçeci E., Read E.J., Leitman S., et al. CD34+ cell dose predicts relapse and survival after T-cell-depleted HLA-identical haematopoietic stem cell transplantation (HSCT) for haematological malignancies. Br J Haematol 108 (2000) 408-414
13. Nakamura R., Bahçeci E., Read E.J., et al. Transplant dose of CD34(+) and CD3(+) cells predicts outcome in patients with haematological malignancies undergoing T cell-depleted peripheral blood stem cell transplants with delayed donor lymphocyte add-back. Br J Haematol 115 (2001) 95-104
14. Horowitz M.M., Gale R.P., Sondel P.M., et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 75 (1990) 555-562
15. Schmitz N., Beksac M., Bacigalupo A., et al. Filgrastim-mobilized peripheral blood progenitor cells versus bone marrow transplantation for treating leukemia: 3-year results from the EBMT randomized trial. Haematologica 90 (2005) 643-648
16. Barrett A.J., Mavroudis D., Tisdale J., et al. T cell-depleted bone marrow transplantation and delayed T cell add-back to control acute GVHD and conserve a graft-versus-leukemia effect. Bone Marrow Transplant 21 (1998) 543-551
17. Jiang Y.Z., Barrett A.J., Goldman J.M., and Mavroudis D.A. Association of natural killer cell immune recovery with a graft-versus-leukemia effect independent of graft-versus-host disease following allogeneic bone marrow transplantation. Ann Hematol 74 (1997) 1-6
18. Kumar S., Chen M.G., Gastineau D.A., et al. Lymphocyte recovery after allogeneic bone marrow transplantation predicts risk of relapse in acute lymphoblastic leukemia. Leukemia 17 (2003) 1865-1870
19. Savani B.N., Rezvani K., Mielke S., et al. Factors associated with early molecular remission after T cell-depleted allogeneic stem cell transplantation for chronic myelogenous leukemia. Blood 107 (2006) 1688-1695
20. Ringden O., Barrett A.J., Zhang M.J., et al. Decreased treatment failure in recipients of HLA-identical bone marrow or peripheral blood stem cell transplants with high CD34 cell doses. Br J Haematol 121 (2003) 874-885
21. Urbano-Ispizua A., Carreras E., Marin P., et al. Allogeneic transplantation of CD34+ selected cells from peripheral blood from human leukocyte antigen-identical siblings: detrimental effect of a high number of donor CD34+ cells?. Blood 98 (2001) 2352-2357
22. Perez-Simon J.A., ez-Campelo M., Martino R., et al. Impact of CD34+ cell dose on the outcome of patients undergoing reduced-intensity-conditioning allogeneic peripheral blood stem cell transplantation. Blood 102 (2003) 1108-1113
23. Sohn S.K., Kim J.G., Kim D.H., et al. Impact of transplanted CD34+ cell dose in allogeneic unmanipulated peripheral blood stem cell transplantation. Bone Marrow Transplant 31 (2003) 967-972
24. Urbano-Ispizua A., Rozman C., Pimentel P., et al. Risk factors for acute graft-versus-host disease in patients undergoing transplantation with CD34+ selected blood cells from HLA-identical siblings. Blood 100 (2002) 724-727
25. Zaucha J.M., Gooley T., Bensinger W.I., et al. CD34 cell dose in granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell grafts affects engraftment kinetics and development of extensive chronic graft-versus-host disease after human leukocyte antigen-identical sibling transplantation. Blood 98 (2001) 3221-3227